Stereotactic body radiotherapy using helical tomotherapy for hepatocellular carcinoma: clinical outcome and dosimetric comparison of Hi-ART vs. Radixact
- Authors
- Bae, Sun Hyun; Cho, Kwang Hwan; Jung, Jae Hong; Kim, Young Seok; Kim, Sang Gyune; Yoo, Jeong-Ju; Lee, Jae Myung; Lee, Min Hee; Lim, Sung Hee
- Issue Date
- Nov-2022
- Publisher
- AME Publishing Company
- Keywords
- Hepatocellular carcinoma; helical tomotherapy (HT); Hi-ART system; Radixact; stereotactic body radiotherapy (SBRT)
- Citation
- Translational Cancer Research
- Journal Title
- Translational Cancer Research
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/21859
- DOI
- 10.21037/tcr-22-1565
- ISSN
- 2218-676X
2219-6803
- Abstract
- <bold>Background</bold>: Helical tomotherapy (HT), a unique rotational dose delivery machine, has been updated from Hi-ART to Radixact. We retrospectively evaluated the treatment outcomes of stereotactic body radiotherapy (SBRT) using HT for hepatocellular carcinoma (HCC) and compared the dosimetric details of Hi-ART and Radixact. <bold>Methods</bold>: Between April 2014 and November 2020, 28 patients with HCC were treated with SBRT using HT for a cure at Soonchunhyang University College of Medicine, Bucheon. According to the Barcelona Clinic Liver Cancer classification, 9 patients had stage 0 disease, 12 had stage A, 4 had stage B, and 3 had stage C. The tumor size ranged from 1 cm to 8 cm (median, 2 cm). The SBRT dose ranged from 40 to 60 Gy (median, 48 Gy) with 4 fractions. Twenty-three patients were treated with Hi-ART and 5 patients were treated with Radixact. To compare the dosimetric parameters between Hi-ART and Radixact, we created treatment plans with the same constraints, pitch, modulation factor, and field width for the same patient in pairs.<bold>Results</bold>: The median follow-up time from the date of SBRT administration was 24 months (range, 3-67 months). The local failure-free survival and intrahepatic failure-free survival rates were 96% and 58% at 1 year, 84% and 36% at 2 years, and 76% and 18% at 3 years, respectively. The overall survival rate was 93% at 1 year, 93% at 2 years, and 53% at 3 years, respectively. When the paired treatment plans were reviewed, the beam-on time and intermediate dose-spillage were found to be significantly reduced in Radixact than Hi-ART (P<0.001). With regard to normal organ sparing, the irradiated dose to the total liver, normal liver, heart, and kidney was significantly lower with Radixact (P<0.001).<bold>Conclusions</bold>: SBRT using HT for HCC showed favorable treatment outcomes. Radixact, the latest version, physically improved treatment efficiency by reducing treatment time and provided better organ sparing than Hi-ART.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Radiology > 1. Journal Articles
- College of Medicine > Department of Internal Medicine > 1. Journal Articles
- College of Medicine > Department of General Surgery > 1. Journal Articles
- College of Medicine > Department of Radiation Oncology > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/21859)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.